Press Releases
Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern
Relmada Therapeutics Selected to Present at 2016 Biotech Showcase™ in San Francisco
Relmada Therapeutics Successfully Completes Multiple Ascending Dose Study of d-Methadone for Neuropathic Pain
Relmada Therapeutics Announces Results of Annual Meeting of Stockholders
Relmada Therapeutics Recommends Stockholders Vote "FOR" Relmada's Director Nominees on the WHITE Proxy Card Today
U.S. Federal Court Grants Preliminary Injunction Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern
Relmada Sends Letter To Stockholders Highlighting Significant Progress In Value Creation Strategy Overseen By Board And Management Team
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Relmada Stockholders Vote the WHITE Proxy Card "FOR" Relmada's Director Nominees: Shreeram Agharkar and Maged Shenouda
Pharmaceutical Industry Leader James Dolan Joins Relmada Therapeutics Advisory Team
U.S. Federal Court Issues Temporary Restraining Order Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern
